{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:18:04Z","timestamp":1782969484068,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/s41408-018-0060-0","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T17:42:24Z","timestamp":1518716544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome"],"prefix":"10.1038","volume":"8","author":[{"given":"Chunyan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Sompallae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-5511","authenticated-orcid":false,"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"60_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/leu.2015.334","volume":"30","author":"C Gu","year":"2016","unstructured":"Gu, C. et al. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 30, 873\u2013882 (2016).","journal-title":"Leukemia"},{"key":"60_CR2","unstructured":"Nandi, D., Cheema, P. S., Jaiswal, N., Nag, A. FoxM1: repurposing an oncogene as a biomarker. Semin. Cancer Biol. (2017) Pii: S1044-579X(17)30061-5."},{"key":"60_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2011","unstructured":"Hose, D. et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96, 87\u201395 (2011).","journal-title":"Haematologica"},{"key":"60_CR4","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold, N. et al. Clonal selection and double hit events involving tumor suppressor genes underlie relapse from chemotherapy: myeloma as a model. Blood 128, 1735\u20131744 (2016).","journal-title":"Blood"},{"key":"60_CR5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131438 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"60_CR6","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","volume":"66","author":"LB Baughn","year":"2006","unstructured":"Baughn, L. B. et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6. Cancer Res. 66, 7661\u20137667 (2006).","journal-title":"Cancer Res."},{"key":"60_CR7","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","volume":"68","author":"E Menu","year":"2008","unstructured":"Menu, E. et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 68, 5519\u20135523 (2008).","journal-title":"Cancer Res."},{"key":"60_CR8","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","volume":"56","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky, R. et al. Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. Leuk. & Lymphoma 56, 3320\u20133328 (2015). 1-9.","journal-title":"Leuk. & Lymphoma"},{"key":"60_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 6, 353\u2013367 (2016).","journal-title":"Cancer Discov."},{"key":"60_CR10","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","volume":"117","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117, 3847\u20133857 (2011).","journal-title":"Blood"},{"key":"60_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","volume":"125","author":"SK Kumar","year":"2015","unstructured":"Kumar, S. K. et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125, 443\u2013448 (2015).","journal-title":"Blood"},{"key":"60_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7471","volume":"6","author":"M Buchner","year":"2015","unstructured":"Buchner, M. et al. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat. Commun. 6, 6471 (2015).","journal-title":"Nat. Commun."},{"key":"60_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3324\/haematol.2011.053421","volume":"97","author":"S Uddin","year":"2012","unstructured":"Uddin, S. et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 97, 1092\u20131100 (2012).","journal-title":"Haematologica"},{"key":"60_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/0008-5472.CAN-15-0828","volume":"76","author":"B Bisikirska","year":"2016","unstructured":"Bisikirska, B. et al. Elucidation and pharmacological targeting of novel molecular drivers of follicular lymphoma progression. Cancer Res. 76, 664\u2013674 (2016).","journal-title":"Cancer Res."},{"key":"60_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0060-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0060-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0060-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:33:41Z","timestamp":1671536021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0060-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0060-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,15]]},"assertion":[{"value":"27 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"22"}}